Otsuka : Notice Regarding Revisions of Consolidated Results Forecast for the first half of FY2022
July 26, 2022 at 12:59 pm IST
Share
July 26, 2022
Company Name
Otsuka Holdings Co., Ltd.
Name of Representative
Tatsuo Higuchi
President and Representative Director, CEO
Code Number
4578, Prime market of the Tokyo Stock
Exchange
Contact
Yuji Kogure
Director, Investor Relations Department
(Phone: +81-3-6361-7411)
Notice Regarding Revisions of Consolidated Results Forecast
for the first half of FY2022
Based on our recent business results, Otsuka Holdings Co., Ltd. (the "Company") hereby revised our consolidated financial forecasts for the first half of FY2022, previously announced on February 10, 2022 and May 13, 2022.
1. Revision of the consolidated financial forecasts for the first half of FY2022
Profit
Business
Operating
Profit before
Profit for the
attributable
Basic
Revenue
to owners of
earnings per
profit
profit
tax
year
the
share
Company
Million yen
Million yen
Million yen
Million yen
Million yen
Million yen
Yen
Previous forecast (A)
767,000
111,000
112,500
112,000
87,500
86,000
158.55
Revised forecast (B)
814,000
78,000
67,000
92,800
71,500
69,800
128.50
Amount of change (B-A)
47,000
(33,000)
(45,500)
(19,200)
(16,000)
(16,200)
Change (%)
6.1%
(29.7%)
(40.4%)
(17.1%)
(18.3%)
(18.8%)
(Reference) Consolidated results
718,815
104,271
111,169
119,207
93,700
91,407
167.68
for the first half of FY2021
2. Reasons for the revision
For the six-month period ended June 30, 2022, business performance was driven by the four global products of the pharmaceutical business (ABILIFY MAINTENA, REXULTI/RXULTI, JINARC/JYNARQUE and LONSURF), as well as the nutraceutical business, and consolidated revenue is progressing ahead of the plan, even if the impact of the yen's depreciation is excluded.
However, the impact of the sudden depreciation of the yen on the elimination of unrealized gains on inventories in the pharmaceutical business is expected to be approximately ¥20.0 billion and cost of sales is expected to increase significantly. In addition, although the Company expects to record a valuation gain of approximately ¥10.0 billion on shares of Cullinan Pearl Corp. (hereinafter referred to as "Cullinan Pearl") it already owns as a result of making Cullinan Pearl, which had been an equity-method affiliate of the Company, a wholly owned subsidiary, the Company expects to record one-time expenses of approximately ¥7.0 billion including expenses associated with the termination of its global license agreements with Akebia Therapeutics, Inc. (hereinafter referred to as "Akebia Therapeutics") in the second quarter of FY2022, in addition to the impairment losses of ¥23.8 billion recorded in the first quarter of FY2022 for
vadadustat, a drug candidate for the treatment of anemia associated with chronic kidney disease, and others. Therefore, business profit, operating profit, profit for the period and profit attributable to owners of the Company are expected to be lower than the previous forecast. There will be no further payments to Akebia Therapeutics associated with the termination of the global license agreements.
Please note that the full-year forecasts for FY2022 (fiscal year ending December 31, 2022) will be announced on July 29, 2022 along with the first half actual financial results.
Note:
The above forecasts are based on information available and certain assumptions that the Company deems reasonable at the time of the announcement. Actual operating results may differ from these projections due to various factors.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Otsuka Holdings Co. Ltd. published this content on 26 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 July 2022 07:28:06 UTC.
Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity:
- manufacture and sale of pharmaceutical products (65.2% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices;
- manufacture and sale of nutraceutical products (25.1%): functional foods and beverages, OTC products, nutritional supplements;
- production of mineral waters, beverages and foods (2.1%);
- other (7.5%): manufacture of functional chemicals and fine chemicals, provision of logistics services, manufacture of electronic products, etc.
Net sales by source of income are divided between sales of products (93.8%), sales of licences and royalties (1.8%) and other (4.4%).
Net sales are distributed geographically as follows: Japan (43.2%), North America (34%),